These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 3088461)

  • 1. [Hyperammonemia in valproate therapy in children and adolescents].
    Laub MC
    Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproate-induced hyperammonemia.
    Batshaw ML; Brusilow SW
    Ann Neurol; 1982 Mar; 11(3):319-21. PubMed ID: 6807193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for hyperammonemia in pediatric patients with epilepsy.
    Yamamoto Y; Takahashi Y; Imai K; Mishima N; Yazawa R; Inoue K; Itoh K; Kagawa Y; Inoue Y
    Epilepsia; 2013 Jun; 54(6):983-9. PubMed ID: 23409971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of valproate, carbamazepine, and levetiracetam on the antioxidant and oxidant systems in epileptic patients and their clinical importance.
    Varoglu AO; Yildirim A; Aygul R; Gundogdu OL; Sahin YN
    Clin Neuropharmacol; 2010 May; 33(3):155-7. PubMed ID: 20502135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy.
    Pylvänen V; Pakarinen A; Knip M; Isojärvi J
    Epilepsy Behav; 2006 May; 8(3):643-8. PubMed ID: 16600693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid function in children with epilepsy treated with sodium valproate monotherapy: a prospective study.
    Attilakos A; Katsarou E; Prassouli A; Mastroyianni S; Voudris K; Fotinou A; Garoufi A
    Clin Neuropharmacol; 2009; 32(1):32-4. PubMed ID: 18978499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of hyperammonemia in stuporous states induced by sodium valproate].
    Warter JM; Marescaux C; Rumbach L; Micheletti G; Chabrier G; Koehl C; Imler M; Collard M
    Rev Neurol (Paris); 1983; 139(12):753-7. PubMed ID: 6420866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist?
    Chicharro AV; de Marinis AJ; Kanner AM
    Epilepsy Behav; 2007 Nov; 11(3):361-6. PubMed ID: 17845866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.
    Yamamoto Y; Takahashi Y; Suzuki E; Mishima N; Inoue K; Itoh K; Kagawa Y; Inoue Y
    Epilepsy Res; 2012 Sep; 101(3):202-9. PubMed ID: 22542569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of the ketogenic diet in pediatric epilepsy: effects of valproate combination therapy.
    Lyczkowski DA; Pfeifer HH; Ghosh S; Thiele EA
    Epilepsia; 2005 Sep; 46(9):1533-8. PubMed ID: 16146450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No effect of co-administered antiepileptic drugs on in-vivo protein binding parameters of valproic acid in patients with epilepsy.
    Suzuki Y; Itoh H; Abe T; Nishimura F; Sato Y; Takeyama M
    J Pharm Pharmacol; 2011 Jul; 63(7):976-81. PubMed ID: 21635265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum lipids, vitamin B12 and folic acid levels in children receiving long-term valproate therapy.
    Geda G; Caksen H; Içağasioğlu D
    Acta Neurol Belg; 2002 Sep; 102(3):122-6. PubMed ID: 12400250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs.
    Ratnaike RN; Schapel GJ; Purdie G; Rischbieth RH; Hoffmann S
    Br J Clin Pharmacol; 1986 Jul; 22(1):100-3. PubMed ID: 3091053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
    Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
    Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
    Tseng YL; Huang CR; Lin CH; Lu YT; Lu CH; Chen NC; Chang CC; Chang WN; Chuang YC
    Medicine (Baltimore); 2014 Sep; 93(11):e66. PubMed ID: 25192484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hyperammonemic encephalopathy associated with valproate acid].
    Osuna MT; Burcet J; Ramió L; Ustrell X; Silva Y; Molins A
    Neurologia; 2003; 18(6):347-50. PubMed ID: 12838456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for development of subclinical hypothyroidism during valproic acid therapy.
    Mikati MA; Tarabay H; Khalil A; Rahi AC; El Banna D; Najjar S
    J Pediatr; 2007 Aug; 151(2):178-81. PubMed ID: 17643774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subclinical hypothyroidism during valproic acid therapy in children and adolescents with epilepsy.
    Kim SH; Chung HR; Kim SH; Kim H; Lim BC; Chae JH; Kim KJ; Hwang YS; Hwang H
    Neuropediatrics; 2012 Jun; 43(3):135-9. PubMed ID: 22618302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.